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ISSUE DEFINITION 
In June 1976, the National Institutes of Health issued the initial version 
of the Recombinant DNA guidelines. The guidelines were developed in response 
to concern from both scientists and the general public about the potential 
hazards of genetic engineering. Other Federal agencies which support 
recombinant  research have adopted the guidelines, and most industries 
have decided to comply with them voluntarily The techniques associated with 
genetic engineering enable the,researcher to recombine DNA (the hereditary 
material of the cell) in a very precise manner. The recombinant DNA can be 
used to manufacture products which have never been produced before by 
bacteria and to manufacture products at a higher rate and yield than 
previously possible. 
After 10 years of experience with recombinant DNA, many believe that 
earlier estimates of risk were exaggerated. This change in perception is 
reflected in the successive modifications of the guidelines over the past 6 
years. Recombinant DNA and the NIH guidelines remain topics of continuing 
concern to the Congress and have been the subject of legislation in previous 
sessions. 
BACKGROUND AND POLICY ANALYSIS 
During a 1968 Senate Subcommittee hearing on a Joint Resolution (S.J. Res. 
145) to establish a new health science commission, Dr. Arthur Kornberg 
directed the subcommittee's attention toward the rapidly progressin'g field of 
molecular biology. He noted that important developments were near fruition 
and that the potential social impact of these advances could be far-reaching. 
Dr. Kornberg was referring to discoveries which would provide the technical 
framework for the spe'cialty commonly known as genetic engineering. New 
techniques have been developed in this field which enable a researcher to 
recombine DNA (the hereditary material of the cell) in a very precise manner. 
The recombinant DNA can provide a cell with the ability to manufacture 
products (for example, insulin) which were previously not part of the cell's 
make-up. 
In 1973, a group of scientists attending a Gordon Conference Session 
chaired by Drs. Maxine Singer and Dieter Sol1 discussed the possibility of 
public health risk associated with genetic engineering. Their concern was 
based upon the conjecture that the new techniques could accidently produce a 
recombinant molecule with hazardous characteristics. For example, it has 
been speculated that an inadvertant modification of DNA in a previously 
harmless organism might enhance its capability of producing a highly 
infectious disease. The session's participants voted in favor of sending a 
letter to the National Academy of Sciences (NAS) suggesting that the academy 
consider the risks associated with genetic engineering and "recommend 
specific actions or guidelines" (Science, July 1973). In response to the 
Gordon Conference letter, NAS appointed a panel of experts to study the risk 
question. After a year of discussion, the panel issued the following three 
recommendations: 
1. Scientists should temporarily postpone certain experiments 
until the risk associated with genetic engineering could be 
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adequately assessed; 
2. The National Institutes of Health (NIH) should establish an 
Advisory Committee which would devise guidelines for 
investigators working with recombinant DNA; and 
3. An international conference of experts should be organized 
to discuss the risk questions associated with recombinant 
DNA. 
The international conference was held in February 1975 at Asilomar, 
California, and was attended by a group of 150 eminent scientists. The final 
report recommended that biological and physical containment standards should 
be assigned to experiments based on their perceived hypothetical risk. 
The original Asilomar report was formalized into the guidelines by the 
newly formed NIH Recombinant DNA Advisory Committee (RAC, which was formed in 
response to the NAS panel's recommendations). After an analysis of the RAC1s 
proposed guidelines and public comments, the Director of NIH, Dr. Donald S. 
Fredrickson, issued the initial version of the guidelines in June 1976 
(Federal Register, v. 41: 27902-27943). This original version of the 
guidelines was only binding on research supported by NIH. 
A special interagency advisory committee was later formed with 
representatives from all Federal agencies which perform, fund, or regulate 
recombinant DNA research. The committee succeeded in gaining agreement among 
its member agencies to adopt the NIH guidelines and to require compliance by 
federally funded researchers in work involving recombinant DNA. While the' 
guidelines are not promulgated by law, an agency can enforce the compliance 
of researchers who receive Federal funds. Even though the guidelines do not 
cover non-federally supported research, most industries have decided to 
comply voluntarily with the guidelines. 
By 1978 it was found that the original guidelines were unnecessarily 
restrictive and that a mechanism for the revision of the guidelines needed to 
be incorporated directly into the document. A series of scientific and 
public meetings were held to discuss the matter, and subsequently a new 
version of the guidelines was published for public Comment in July 1978 
(Federal Register, v. 43: 60080-601005). Following a public hearing in 
September 1978, the guidelines were reissued and became effective on Dec. 
22, 1978 (Federal Register, v. 43: 60108-60131). The 1978 version contains 
a mechanism for the future revision of the document. Proposals which would 
modify any section or introduce a new section into the guidelines must be 
published in the Federal Register at least 30 days prior to a RAC meeting. 
The proposal and any public comments are discussed by the RAC in an open 
public session. The NIH Director then reviews the RAC's recommendations and 
makes a final decision upon the proposal. 
On Dec. 29, 1978, 14 new members were added to the RAC, including six 
non-biologists. This broadening of the committee's composition was in 
compliance with a new provision contained within the 1978 version of the 
guidelines. 
There have been many modifications of the guidelines since the 
implementation of the revision procedures. Three complete republications 
have been issued since 1978: 
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1. January 1980 -- This modification lowered the physical 
containment requirements for some, but not all, recombinant 
DNA experiments which use a particular strain of bacterium 
(E. coli K-12). Approximately 80% of all studies use this 
laboratory strain of bacteria as a host cell for recombinant 
DNA. In addition, a large percentage of principal investigators 
using this particular strain of bacteria were no longer required 
to notify NIH of the details of their experiments. Notification 
of a local review board (the Institutional Biosafety Committee 
or IBC) was all that was required (Federal Register, v. 45: 
6724-6749, 1980). 
2. November 1980 -- The physical containment requirements 
were lowered and more changes were made in the notification 
procedures required of principal investigators (Federal 
Register, v. 45: 77384-77408). 
3. July .I1981 -- In response to a letter from representatives 
of tire Institutional Biosafety Committees (IBCs), the RAC 
voted to exempt research with E. coli K-12 (and 
a few other host systems) from the guideline regulations 
(Federal Register, v. 46: 34462-34487). 
Several attempts were made in previous Congresses to focus attention on 
recombinant DNA issues through hearings, proposed legislation, and reports. 
Congressional committees have identified the evolution of this issue as a 
matter of vital public policy concern and have suggested the need to monitor 
research continuously in order to be prepared for further legislative action 
if necessary. Legislation which would regulate and study the implications of 
research involving recombinant DNA was introduced during the 95th Congress. 
Several bills proposed the establishment of new Federal regulatory .powers, 
ranging from declaring a total moratorium on the research until a risk 
assessment could be completed to setting up licensing and certification 
procedures for researchers and laboratories. Four congressional committees 
(2 House, 2 Senate) held extensive hearings on the DNA issues in 1977, with 
some continued legislative hearings in 1978. Two major bills (S. 1217 and 
H.R. 11192) each received final full committee action in their respective 
houses, but none of the legislation reached the floor during the 95th 
Congress. In the 96th Congress, one major bill was introduced, S. 2234. 
This bill would have required persons not covered by the NIH guidelines to 
notify the Secretary of the U.S. Department of Health, Education, and 
Welfare (HEW -- now the Department of Health and Human Services (HHS)) of 
their activities in the area of genetic engineering research and 
applications. Non-federally supported institutions and industry would have 
been affected by this bill, but there was no congressional action on S. 2234. 
While the Federal Government has not passed any legislation directly 
regulating recombinant DNA research, several States and local governments 
have adopted ordinances regulating this type of research. In addition, bills 
were introduced on this subject in a number of States in recent years. 
On Apr. 23, 1981, the RAC discussed a proposal, introduced by Drs. Allen 
Campbell and David Baltimore, which would transform the guidelines into a 
voluntary code of laboratory practice. The Baltimore-Campbell proposal would 
have reduced the physical containment levels for most recombinant DNA 
experiments with the exception of prohibited experiments. The proposal also 
would have eliminated all punishments for failing to follow the guidelines. 
The committee voted to have a special panel review the guidelines and make 
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recommendations. The Working Group on Revision of the Guidelines was 
appointed at the April meeting and met on June 1 and July 9, 1981. The group 
did not agree that the NIH guidelines should be made voluntary. However, it 
did suggest that detailed rules for the composition of the local IBCs be 
removed from the guidelines. 
At the RAC's September 10-11 meeting, Dr. David Baltimore offered a new 
proposal which mixed portions of the original Baltimore-Campbell proposal 
with the working group's recommendations. The RAC developed its own proposal - - 
for publication in the Federal Register, (v. 46: 59368-59425, Dec. 4 ,  1981) 
by modifying Dr. Baltimore's proposal. The new RAC proposal differed from 
the Baltimore-Campbell proposal in that it eliminated the prohibition of 
experiments, but instead retained admonishments against the cloning of toxin 
genes and drug resistance traits in organisms which do not already have these 
characteristics. 
An alternative proposal appeared in the Federal Register, on Dec. 7, 1981 
(v. 46: 59734-59737) at the request of Dr. Susan Gottesman, Chairman of the 
Working Group. The Gottesman proposal differs from the previously discussed 
proposals in that the guidelines would remain mandatory for institutions 
receiving NIH funding. In addition, certain experiments would require prior 
review by either NIH or an IBC. At the Feb. 8, 1982, meeting of the RAC, the 
committee voted in favor of the Gottesman proposal, 17 for and 3 against. 
The Gottesman proposal was accepted by the Acting Director of NIH and 
published in the April 21, 1982, Federal Register. At the June 28, 1982, RAC 
meeting, the committee decided not to include within the guidelines a 
prohibition against the use of recombinant DNA for the development of 
biological warfare agents. An existing international convention, adopted in 
1972 by many countries including the U.S.. and the Soviet Union, prohibits 
development of biological weapons. The committee concluded that the 
convention's prohibitions were broad enough to cover work involving the use 
of recombinant DNA techniques. 
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CHRONOLOGY OF EVENTS 
06/28/82 -- RAC voted against including within the guidelines 
prohibitions against the use of recombinant DNA 
in developing biological warfare agents. 
04/21/82 -- Republication of NIH Guidelines in Federal 
Register, Gottesman revision. (v. 47: 
17180-17198) 
02/09/82 -- RAC voted in favor of Gottesman proposal 17 to 3. 
12/07/81 -- Gottesman Proposal published in the Federal Register 
(v. 46: 59734-59737) . 
12/04/81 -- R A C t s  Guideline revision published in Federal 
Register (v. 46: 59368-59425). 
09/10/81 -- David Baltimore proposed a compromise between 
Baltimore Campbell proposal and the Working Group 
proposal. RAC modified the Baltimore proposal. 
07/09/81 -- Working Group on the Revision of the NIH Guidelines 
met for second time. 
07/01/81 -- Republication of NIH Guidelines in Federal Register 
exempting all research with E coli K-12 from the 
Guidelines (v.. 46: 34462-34487). 
06/01/81 -- Working Group on the Revision of the NIH Guidelines, 
met for first time. 
04/23/81 -- Baltimore-Campbell proposal discussed by RAC. 
11/21/80 -- Republication of NIH Guidelines in Federal 
Register lowering physical containment requirements 
for additional host cells. Change notification 
procedures required of principal investigators ( v .  
45: 77384-77408). 
06/16/80 -- Supreme Court rules 5-4 that life forms created 
in the laboratory by genetic engineering may be 
patented like any other invention. 
01/29/80 -- S. 2234 introduced by Senator Stevenson and 
referred to Committee on Labor and Human Resources. 
01/29/80 -- Republication of the NIH Guidelines in Federal 
Register lowering physical containment requirements 
for experiments using E. coli K-12 ( v .  45: 
6724-6749). 
11/30/79 -- NIH recombinant DNA research proposed guidelines 
published in the Federal Register (v. 44: 
69210-69251). 
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04/02/79 -- NIH proposed plan for a program to assess the risks 
of recombinant DNA research. Federal Register, 
(v. 44: 19301-19304) . 
12/29/78 -- Fourteen new members were named to the NIH 
Recombinant DNA Advisory Committee. 
12/22/78 -- FDA announced intent to propose regulations for 
recombinant DNA (Federal Register, Dec. 22, 1978: 
60134-60135). 
-- NIH Revised Guidelines regarding the conduct of 
research involving recombinant DNA were published 
(Federal Register, Dec. 22, 1978: 60080-60105; 
60108-60131). 
07/28/78 -- Proposed revised guidelines for the conduct of 
recombinant DNA research published Federal 
Register, v. 43: 33041-33178. 
Also includes an Environmental Impact Assessment). 
02/28/78 -- H.R. 11192 introduced in House. 
12/15/77 - 12/16/77 -- NIH Public Meeting on the Recombinant 
DNA Guidelines. 
11/28/77 -- The availability of the NIH Environmental 
Impact Statement on Guidelines for Research 
Involving Recombinant DNA Molecules (October 
1977) was noted in the Federal Register. 
10/26/77 -- S. 1217' (Recombinant DNA Regulation Act) was 
placed on the Senate calendar under "Subject 
on the Tablep1 at the request of Senator Robert 
Byrd. 
09/27/77 -- Proposed revised NIH guidelines for the conduct 
of recombinant DNA research were published 
(Federal Register v. 42, no. 187, part 111: 
49595-49609). 
06/22/77-06/23/77 -- The NIH Advisory Committee met again 
(see May 14-15, 1977 entry) to continue consideration 
of the DNA research guidelines revision. 
05/14/77-05/15/77 -- The NIH Recombinant DNA Molecule Program 
Advisory Committee met to consider revision of the 
recombinant DNA research guidelines. 
03/15/77 - 03/17/77 -- Subcommittee on Health and Environment, 
House Interstate and Foreign Commerce Committee, 
held hearings on H.R. 4759 (and other bills): 
recombinant DNA. 
03/06/77 -- House Science and Technology Committee released 
report "Genetic Engineering, Human Genetics, 
and Cell Biology" (see REPORTS). 
09/06/76 -- DHEW-NIH Recombinant DNA Research Guidelines -- 
Draft Environmental Impact Statement, was 
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published (Federal Register: 38426-38438). 
07/07/6 -- DHEW-NIH Recombinant DNA Research Guidelines 
were published (Federal Register: 27942-27943). 
02/09/76 - 02/10/76 -- First meeting of the NIH Director's 
Advisory Committee was held to review the 
proposed guidelines concerning recombinant DNA 
research. 
04/22/75 -- Genetic Engineering was the subject-of hearings 
before the Subcommittee on Health, Senate 
Committee on Labor and Public Welfare. 
02/24/75 -- NAS-NSF-NIH supported Conference on Recombinant 
DNA Research, held in Asilomar, Calif. 
l0/07/74 -- NIH Recombinant DNA Advisory Committee was 
established. 
06/11/73 -- Gordon Conference on Nucleic Acids was held in 
New Hampton, N.H. 
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